FIELD: pharmaceutical industry.
SUBSTANCE: group of inventions relates to ex-vivo methods of producing activated platelet-enriched plasma and to a method of producing a thrombocyte gel with a given mechanical strength of clots in a thrombocyte gel. Ex-vivo method of producing an activated platelet-enriched plasma (POP) sample involves: obtaining a platelet-enriched plasma sample for activation, adding calcium ions to the obtained sample of POP in a concentration which is selected based on the specified parameters in the activated POP sample selected from clot formation time and/or mechanical strength of the clots; placing an POP sample between the electrodes of the electromagnetic stimulation device; establishing a set of electric pulse parameters based on said concentration of calcium ions and said specified parameters of the activated sample of POP and exposing the sample of POP with added calcium ions to one or more electrical pulses generated in accordance with the set values of electric pulse parameters, to obtain an activated POP sample containing one or more growth factors and having said preset parameters (versions). Method of producing thrombocyte gel with given mechanical clots strength in thrombocyte gel, where the given mechanical strength of the clots is greater than the strength observed when the platelet gel is formed using only thrombin, where the method involves: selecting a concentration of calcium ions based on a given mechanical strength of clots in the thrombocyte gel; formation of thrombocyte gel by activating a platelet-enriched plasma sample containing calcium ions in the selected concentration, where the POP sample is activated by electrostimulation to obtain a platelet gel containing clots having a given mechanical strength.
EFFECT: above-described group of solutions enables to create an activated platelet product, in which one or more parameters are controlled from the presence or absence of a clot, clot formation time (if any) and/or mechanical strength of clots (if any) by the presence of calcium ions or their concentration during activation.
18 cl, 7 tbl, 10 dwg
Title | Year | Author | Number |
---|---|---|---|
SERUM FRACTION OF THROMBOCYTE-ENRICHED FIBRIN | 2014 |
|
RU2711330C2 |
THROMBOCYTE ACTIVATION AND GROWTH FACTOR RELEASE USING ELECTRIC PULSES | 2015 |
|
RU2712234C2 |
METHOD FOR PRODUCING AUTOLOGOUS FIBRIN WITH CONTROLLED FIBRINOGEN CONTENT WITHOUT USING EXOGENOUS THROMBIN | 2020 |
|
RU2758260C1 |
METHOD FOR OBTAINING PLATELET RELEASATE CONTAINING GROWTH FACTORS | 2017 |
|
RU2795884C2 |
METHOD FOR OBTAINING A SOLUTION OF GROWTH FACTORS FROM PLATELETS | 2022 |
|
RU2790701C1 |
SOLUTION FOR CORRECTION OF PRIMARY HOMEOSTASIS DISORDER WITH PLASMA-SUBSTITUTING SOLUTIONS OF NOVEL COMPOSITION | 2005 |
|
RU2300385C1 |
WHOLE BLOOD THROMBINE ACTIVITY TEST | 2006 |
|
RU2422835C2 |
USE OF PINANYLSULFIDE WITH METHYL MERCAPTOACETATE FRAGMENT - METHYL 2-({[(1S,2R,5S)-6,6-DIMETHYLBICYCLO[3.1.1]HEPT-2-YL]METHYL}THIO) ACETATE, AS AN AGENT WITH INHIBITORY EFFECT ON PLATELET ACTIVATION | 2015 |
|
RU2671567C2 |
THROMBOSIS MONITOR AND METHOD OF THROMBOSIS MONITORING | 2006 |
|
RU2432577C2 |
METHOD OF PRODUCING PLATELET-ENRICHED FIBRIN MATRIX OF VARIOUS SHAPES AND SIZES | 2023 |
|
RU2811233C1 |
Authors
Dates
2021-02-11—Published
2016-12-29—Filed